Healthy Skepticism Library item: 8747

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Mendell JR, Csimma C, McDonald CM, Escolar DM, Janis S, Porter JD, Hesterlee SE, Howell RR.
Challenges in drug development for muscle disease: a stakeholders' meeting.
Muscle Nerve 2007 Jan; 35:(1):8-16
http://www3.interscience.wiley.com/cgi-bin/abstract/113441314/ABSTRACT?CRETRY=1&SRETRY=0

Abstract:

Current treatment benefits for patients with muscle disease are limited, but progress in legislative and scientific initiatives have set the stage for the development of new therapies. The MD-CARE Act (Public Law 107-84), which allocates federal resources to muscular dystrophy, was approved by Congress and signed into law by the President of the United States in 2001. This has shifted the emphasis toward translational research. To facilitate a push toward therapy for muscle disorders, the Muscular Dystrophy Association (MDA) sponsored a meeting with representatives from industry, the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and other government agencies and academia. Each contributed in different ways. The FDA helped define the necessary data to support investigational new drug (IND) applications including the design of proof-of-principle studies, outcome measures for clinical trials, and the pathway for developing surrogate measures for fast-tracking promising new drugs. The NIH, other government agencies, and the MDA described potential funding sources for translational research. Industry delineated a complementary role with academia, and academic investigators elucidated the current strengths and weaknesses of available clinical endpoints. The meeting provided a format for communication for diverse disciplines that usually have no common meeting ground, helping to lay the foundation for bringing products to market in a timely fashion.

Keywords:
Publication Types: Congresses MeSH Terms: Academic Medical Centers Animals Clinical Trials/economics Clinical Trials/legislation & jurisprudence* Drug Approval/legislation & jurisprudence Drug Approval/methods Drug Design* Drug Evaluation/economics* Drug Evaluation/legislation & jurisprudence Drug Evaluation/trends Drug Industry Humans Investments Muscular Diseases/drug therapy* National Institutes of Health (U.S.) Outcome Assessment (Health Care) Research Research Support/legislation & jurisprudence* United States United States Food and Drug Administration